Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 2,210 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CEO Abraham Ceesay sold 2,210 shares of the business’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $29.16, for a total transaction of $64,443.60. Following the completion of the transaction, the chief executive officer owned 450,035 shares in the company, valued at approximately $13,123,020.60. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Abraham Ceesay also recently made the following trade(s):

• On Wednesday, October 7th, Abraham Ceesay sold 1,147 shares of Rapport Therapeutics stock. The stock was sold at an average price of $30.66, for a total transaction of $35,167.02.
• On Tuesday, October 6th, Abraham Ceesay sold 3,375 shares of Rapport Therapeutics stock. The stock was sold at an average price of $32.03, for a total transaction of $108,101.25.
• On Wednesday, September 23rd, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $39.17, for a total transaction of $86,565.70.
• On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $45.61, for a total transaction of $374,458.10.
• On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The shares were sold at an average price of $49.57, for a total transaction of $937,913.97.
• On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58.
• On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total value of $1,042,746.66.
• On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $42.11, for a total value of $93,063.10.

Rapport Therapeutics Price Performance

NASDAQ RAPP opened at $25.93 on Friday. The firm has a market cap of $1.24 billion, a PE ratio of -8.53 and a beta of 1.22. Rapport Therapeutics, Inc. has a one year low of $23.75 and a one year high of $52.93. The stock’s 50 day simple moving average is $39.01 and its 200 day simple moving average is $38.93.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, equities analysts expect that Rapport Therapeutics, Inc. will post -4.08 earnings per share for the current year.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Sigma Planning Corp bought a new position in Rapport Therapeutics in the 3rd quarter valued at $1,008,000. Sterling Capital Management LLC increased its stake in shares of Rapport Therapeutics by 597.9% in the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after buying an additional 843 shares during the period. Engineers Gate Manager LP bought a new stake in shares of Rapport Therapeutics during the second quarter worth $888,000. Wellington Management Group LLP raised its position in shares of Rapport Therapeutics by 11.2% during the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock worth $3,625,000 after acquiring an additional 8,757 shares during the last quarter. Finally, Artia Global Partners LP bought a new stake in shares of Rapport Therapeutics during the second quarter worth $5,772,000.

Analysts Set New Price Targets

RAPP has been the topic of several research analyst reports. Raymond James Financial restated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a report on Tuesday. Wolfe Research started coverage on Rapport Therapeutics in a report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price target for the company. Citigroup reiterated an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Rapport Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Rapport Therapeutics presently has an average rating of “Buy” and a consensus target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.